Korea Chorus "Preparing for Domestic Introduction of Sputnik V Vaccine"

The second dose validation badge shipment of Korea Chorus's 'Sputnik V' vaccine is being loaded onto a plane for dispatch to Russia. (Photo by Korea Chorus)

[Asia Economy Reporter Kim Ji-hee] Korea Chorus announced on the 23rd that it has requested the Russian Sovereign Wealth Fund (RDIF) for the documents necessary for approval to use the Russian-made COVID-19 vaccine Sputnik V in preparation for its possible introduction into South Korea. According to Korea Chorus, RDIF is also preparing to send the requested documents.

A Korea Chorus official stated, "We maintain a continuous strategic partnership with RDIF, enabling smooth cooperation," and added, "Domestically, we are preparing the necessary materials for approval, and we are currently confirming with the regulatory authorities what other requirements are needed."

Korea Chorus, a subsidiary of the domestic bio company GL Rapha, previously signed a contract with RDIF to manufacture the Sputnik V vaccine under consignment in South Korea. They plan to produce a total of 150 million doses. Additionally, through a consortium with domestic companies, they plan to produce 500 million doses.

Meanwhile, Korea Chorus sent production batches for 'validation,' a procedure that verifies whether products continuously meet the specified standards and quality elements set for a particular process, to Russia. The validation batch was produced at Korea Chorus's Chuncheon plant.

This content was produced with the assistance of AI translation services.